Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Sarepta (SRPT) to $75 from $100 and keeps an Overweight rating on the shares. With 2nd fatal AE occurring just 3 months after the 1st one, it is understandable investor confidence took a hard hit, but the firm thinks the selloff is pricing in more downside than may be reasonably expected.
Claim 55% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target lowered to $29 from $89 at Barclays
- Sarepta initiated with a Peer Perform at Wolfe Research
- Buy Rating for Sarepta Therapeutics Amid Safety Concerns and Regulatory Challenges
- Cautious Hold Rating on Sarepta Therapeutics Amid Safety Concerns with Elevidys Treatment
- Sarepta downgraded to Equal Weight from Overweight at Morgan Stanley